Biovie Inc stock is traded at $1.32, with a volume of 44,293. It is up +9.09% in the last 24 hours and down -8.33% over the past month. BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.
Previous Close:
$1.21
Open:
$1.25
24h Volume:
44,293
Relative Volume:
0.03
Market Cap:
$11.46M
Revenue:
-
Net Income/Loss:
-$19.92M
P/E Ratio:
-
EPS:
-$4.27
Net Cash Flow:
-$20.51M
1W Performance:
-7.69%
1M Performance:
-8.33%
6M Performance:
-20.48%
1Y Performance:
-12.00%
1-Day Range:
$1.23$1.35
1-Week Range:
$1.11$2.66
52-Week Range:
$0.82$3.79
Biovie Inc Stock (BIVI) Company Profile
Name
Biovie IncSector
HealthcareIndustry
BiotechnologyPhone
775-888-3162Address
680 W NYE LANE, CARSON CITY, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS